Ventilator-Associated Pneumonia — Part 3: Diagnosis & Antimicrobial Treatment
Clinical diagnostic criteria, CPIS scoring table, microbiologic sampling strategies (ETA, BAL, mini-BAL) with quantitative thresholds, biomarker guidance, empiric antibiotic selection stratified by MDR risk with complete dosing tables and renal adjustments, de-escalation principles, short-course duration evidence, inhaled antibiotics, and treatment failure evaluation.
10. Diagnostic Approach to VAP
10.1 Clinical Suspicion Criteria
VAP should be suspected in any mechanically ventilated patient (intubated ≥ 48 hours) who develops a new or progressive pulmonary infiltrate on chest imaging PLUS at least two of the following clinical features:12
- Fever: Temperature > 38.0 °C (or hypothermia < 36.0 °C)
- Leukocytosis or leukopenia: WBC > 12,000 cells/μL or < 4,000 cells/μL
- Purulent tracheobronchial secretions: New onset or change in character (increased volume, thickened, or change in color to yellow/green)
Additional supportive findings (not required for diagnosis):
- Worsening gas exchange (declining PaO2/FiO2 ratio, increasing FiO2 or PEEP requirements)
- Hemodynamic instability or new sepsis
- Increasing minute ventilation or tachypnea
Diagnostic challenge: Each individual clinical criterion has poor specificity for VAP. Fever and leukocytosis are extremely common in ICU patients from non-infectious causes (drug fever, transfusion reactions, adrenal insufficiency, pancreatitis, DVT). Purulent secretions are present in up to 50% of intubated patients without pneumonia due to tracheobronchitis. New infiltrates may represent atelectasis, ARDS, pulmonary edema, hemorrhage, or organizing pneumonia. The combination of clinical criteria has a sensitivity of approximately 69% and specificity of only 75% for histopathologically confirmed VAP.1
10.2 Clinical Pulmonary Infection Score (CPIS)
The CPIS was developed to standardize the clinical assessment of VAP and improve diagnostic accuracy by combining clinical, radiographic, and microbiologic variables into a numerical score.3
CPIS Scoring Table
| Parameter | 0 Points | 1 Point | 2 Points |
|---|---|---|---|
| Temperature (°C) | ≥ 36.5 and ≤ 38.4 | ≥ 38.5 and ≤ 38.9 | ≥ 39.0 or ≤ 36.0 |
| Blood leukocytes (cells/μL) | ≥ 4,000 and ≤ 11,000 | < 4,000 or > 11,000 | < 4,000 or > 11,000 PLUS band forms ≥ 50% |
| Tracheal secretions | Few | Moderate, non-purulent | Abundant AND purulent |
| Oxygenation: PaO2/FiO2 (mmHg) | > 240 or ARDS | — | ≤ 240 and no evidence of ARDS |
| Chest radiograph | No infiltrate | Diffuse or patchy infiltrate | Localized infiltrate |
| Culture of tracheal aspirate | No or light growth | — | Moderate or heavy growth PLUS pathogenic organism consistent with Gram stain |
Interpretation:
| CPIS Score | Interpretation | Action |
|---|---|---|
| < 6 | VAP unlikely | Consider alternative diagnoses; withhold antibiotics if clinical suspicion is low; repeat assessment at 48–72 hours |
| ≥ 6 | VAP likely | Obtain lower respiratory tract cultures; initiate empiric antibiotics |
Limitations of CPIS:
- Sensitivity 65–77%, specificity 42–85% — performance varies substantially across studies
- Subjective components (secretion assessment, radiograph interpretation) limit inter-rater reliability
- Does not reliably distinguish VAP from ventilator-associated tracheobronchitis (VAT) or non-infectious conditions
- The 2016 guidelines from the major American thoracic and infectious disease professional societies do not endorse CPIS as a sole diagnostic tool but acknowledge its potential role in serial assessment (CPIS at day 0 and day 3) to guide antibiotic de-escalation or discontinuation.1
- Modified CPIS variants have been proposed but lack adequate validation for clinical decision-making
10.3 Microbiologic Sampling
The 2016 guidelines recommend obtaining lower respiratory tract samples for culture before initiating or changing antibiotics, though antibiotic initiation should not be delayed while awaiting sampling.12
Sampling Methods Comparison
| Method | Technique | Quantitative Threshold | Sensitivity | Specificity | Advantages | Disadvantages |
|---|---|---|---|---|---|---|
| Endotracheal aspirate (ETA) | Blind suctioning via ETT; quantitative culture of aspirate | ≥ 10^5 CFU/mL (semi-quantitative: moderate to heavy growth) | 75–90% | 40–70% | Non-invasive; no bronchoscopy needed; can be performed by RT/nurse; rapid | High rate of false positives due to colonization; lower specificity |
| Bronchoalveolar lavage (BAL) | Bronchoscopic wedge in affected segment; 120–240 mL sterile saline instilled and retrieved | ≥ 10^4 CFU/mL | 73–93% | 45–100% | Directs sampling to affected area; higher specificity; allows cytology | Requires bronchoscopy; brief desaturation/hemodynamic changes; operator dependent |
| Mini-BAL (blind BAL) | Non-bronchoscopic; catheter advanced blindly through ETT until wedged | ≥ 10^4 CFU/mL | 63–100% | 66–96% | Does not require bronchoscopy; faster and less costly; can be performed by trained RT | Blind technique; cannot target specific segments; risk of sampling non-affected areas |
| Protected specimen brush (PSB) | Bronchoscopic double-catheter brush; protected from upper airway contamination | ≥ 10^3 CFU/mL | 33–100% | 50–100% | Reduces contamination from upper airway | Samples small area; lower sensitivity; rarely used in current practice |
Key recommendation from the 2016 guidelines:
The guidelines suggest non-invasive sampling with semi-quantitative cultures (i.e., endotracheal aspirate with semi-quantitative reporting) as the preferred initial approach, citing equivalent clinical outcomes between invasive (BAL/PSB) and non-invasive (ETA) strategies in a landmark Canadian RCT (n = 740).14
However, the European guidelines express a preference for quantitative cultures from invasive sampling (BAL), particularly when available, to improve specificity and guide more precise antibiotic de-escalation.2
Practical approach:
- Obtain ETA (semi-quantitative or quantitative) as the first-line sampling method in all patients with suspected VAP
- Consider BAL or mini-BAL when:
- ETA is non-diagnostic or discordant with clinical presentation
- Immunocompromised patients (broader differential diagnosis)
- Prior antibiotic failure (to identify resistant organisms or alternative diagnoses)
- Need for cytologic analysis (e.g., eosinophilic pneumonia, DAH)
- All samples should be sent before new antibiotics are started, but treatment initiation should not be delayed
10.4 Blood Cultures and Urinary Antigens
| Test | Indication | Yield | Notes |
|---|---|---|---|
| Blood cultures (2 sets from separate sites) | All patients with suspected VAP | Positive in 8–20% of VAP cases | A positive blood culture with the same organism as respiratory cultures strongly supports the diagnosis; also identifies concurrent bacteremia from other sources |
| Urinary antigen — Legionella pneumophila serogroup 1 | Suspected Legionella (travel, water exposure, immunosuppression, community-acquired presentation) | Sensitivity 70–90% for serogroup 1; does not detect other serogroups or Legionella spp. | Remains positive for weeks after infection |
| Urinary antigen — Streptococcus pneumoniae | Not routinely recommended in VAP (more useful in CAP) | Moderate sensitivity | May be positive from prior colonization; more relevant to community-acquired presentation |
10.5 Biomarkers in VAP Diagnosis
No single biomarker is sufficiently accurate to confirm or exclude VAP in isolation. Biomarkers should be used as adjuncts to clinical judgment.56
| Biomarker | Role in VAP | Sensitivity | Specificity | Clinical Application |
|---|---|---|---|---|
| Procalcitonin (PCT) | Distinguishing bacterial infection from non-infectious inflammation; guiding antibiotic de-escalation/discontinuation | 67–78% (for diagnosis) | 56–83% (for diagnosis) | Better suited for guiding antibiotic duration than for initial diagnosis; a PCT < 0.5 ng/mL or decline of ≥ 80% from peak supports antibiotic discontinuation |
| C-reactive protein (CRP) | Non-specific marker of inflammation | 56–86% | 43–79% | Limited by poor specificity; serial trending (decline by day 4 of treatment suggests adequate therapy) may be more useful than single values |
| Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) | Investigated as a rapid BAL fluid biomarker for bacterial pneumonia | 75–98% | 73–90% | Not widely available; studied primarily in BAL fluid; promising but not recommended for routine clinical use |
| BAL fluid cell count | ≥ 2–3% intracellular organisms on direct microscopy has moderate specificity for VAP | 37–100% | 89–100% | Rapid (available within 1–2 hours of bronchoscopy); highly specific when positive; low sensitivity |
11. Empiric Antibiotic Therapy
11.1 Risk Stratification for MDR Pathogens
The cornerstone of empiric antibiotic selection for VAP is risk stratification for multidrug-resistant (MDR) organisms. The 2016 guidelines identify specific risk factors that should guide empiric regimen breadth.1
Risk Factors for MDR VAP
| Risk Factor | Rationale |
|---|---|
| Prior intravenous antibiotic use within 90 days | Selects for resistant organisms in the oropharynx and GI tract |
| Hospitalization ≥ 5 days before VAP onset | Longer exposure to nosocomial flora; higher colonization with MDR organisms |
| Septic shock at time of VAP diagnosis | Need for broader coverage given high mortality of inadequate therapy |
| Acute respiratory distress syndrome preceding VAP | Associated with prolonged ventilation and antibiotic exposure |
| Acute renal replacement therapy before VAP onset | Marker of critical illness severity; associated with MDR risk |
| Local MRSA prevalence > 10–20% among S. aureus ICU isolates | Unit-specific risk for MRSA VAP |
| Local MDR gram-negative prevalence > 10–20% among gram-negative ICU isolates | Unit-specific risk for resistant Pseudomonas, Acinetobacter, ESBL Enterobacterales |
MDR Risk Stratification Decision Framework
Does the patient have ANY of the following?
• IV antibiotics within 90 days
• Hospitalized ≥ 5 days
• Septic shock at VAP onset
• ARDS preceding VAP
• RRT before VAP onset
┌─── NO to ALL ───────────────────────────────────────┐
│ │
│ LOW MDR RISK → Empiric monotherapy │
│ (Section 11.2) │
│ │
└──────────────────────────────────────────────────────┘
┌─── YES to ANY ──────────────────────────────────────┐
│ │
│ HIGH MDR RISK → Dual gram-negative coverage │
│ ± MRSA coverage (Section 11.3) │
│ │
└──────────────────────────────────────────────────────┘
Additional consideration:
• If unit MRSA prevalence > 10–20% OR patient has MRSA risk
factors → ADD anti-MRSA agent
• If unit MDR gram-negative prevalence > 10–20% → USE two
anti-pseudomonal agents from DIFFERENT classes
11.2 Empiric Therapy — Low MDR Risk (Monotherapy)
For patients with no risk factors for MDR pathogens and in units where local MDR prevalence is ≤ 10–20%, empiric monotherapy with a single anti-pseudomonal agent is recommended:1
| Agent | Standard Adult Dose | Infusion Strategy | Key Notes |
|---|---|---|---|
| Piperacillin-tazobactam | 4.5 g IV every 6 hours | Standard (30 min) or extended (3–4 hours) | Broad gram-negative and anaerobic coverage; well-tolerated |
| Cefepime | 2 g IV every 8 hours | Standard (30 min) or extended (3–4 hours) | Excellent gram-negative coverage including Pseudomonas; no anaerobic activity |
| Levofloxacin | 750 mg IV every 24 hours | 60–90 min infusion | Alternative for beta-lactam allergy; rising Pseudomonas resistance limits utility in some units |
| Imipenem-cilastatin | 500 mg IV every 6 hours | 30 min infusion | Reserve carbapenems when possible; broader than needed for low-risk patients |
| Meropenem | 1 g IV every 8 hours | Standard (30 min) or extended (3 hours) | As above; prefer beta-lactam/beta-lactamase inhibitors or cephalosporins first-line |
Renal Dose Adjustments — Monotherapy Agents
| Agent | CrCl 30–50 mL/min | CrCl 10–29 mL/min | CrCl < 10 mL/min or HD | CRRT |
|---|---|---|---|---|
| Piperacillin-tazobactam | 3.375 g IV q6h | 2.25 g IV q6h | 2.25 g IV q8h (give dose after HD) | 3.375–4.5 g IV q6–8h (institution-specific) |
| Cefepime | 2 g IV q12h | 1 g IV q12h | 1 g IV q24h (give dose after HD) | 1–2 g IV q12h |
| Levofloxacin | 750 mg IV q48h | 750 mg IV q48h | 500 mg IV q48h (give dose after HD) | 750 mg IV q48h |
| Imipenem-cilastatin | 500 mg IV q6–8h | 250 mg IV q6h | 250 mg IV q12h | 250–500 mg IV q6–8h |
| Meropenem | 1 g IV q12h | 500 mg IV q12h | 500 mg IV q24h | 1 g IV q12h |
11.3 Empiric Therapy — High MDR Risk (Combination Therapy)
For patients with one or more risk factors for MDR organisms, empiric therapy should include two anti-pseudomonal agents from different classes and, when indicated, an anti-MRSA agent.12
Gram-Negative Coverage — Choose TWO Agents from Different Classes
Class 1 — Anti-pseudomonal beta-lactam (choose one):
| Agent | Standard Adult Dose | Infusion Strategy |
|---|---|---|
| Piperacillin-tazobactam | 4.5 g IV every 6 hours | Extended infusion (3–4 hours) preferred in critically ill patients |
| Cefepime | 2 g IV every 8 hours | Extended infusion (3–4 hours) preferred |
| Ceftazidime | 2 g IV every 8 hours | Standard (30 min) or extended infusion |
| Meropenem | 1–2 g IV every 8 hours | Extended infusion (3 hours) preferred; use 2 g for suspected Pseudomonas with elevated MICs |
| Imipenem-cilastatin | 500 mg IV every 6 hours | 30 min infusion |
| Aztreonam | 2 g IV every 8 hours | 30 min infusion; alternative for severe beta-lactam allergy (cross-reactivity is negligible) |
Class 2 — Non-beta-lactam anti-pseudomonal agent (choose one):
| Agent | Standard Adult Dose | Key Notes |
|---|---|---|
| Amikacin | 15–20 mg/kg IV every 24 hours (based on ABW) | Target peak 56–64 mg/L, trough < 4 mg/L; monitor renal function and levels |
| Gentamicin | 5–7 mg/kg IV every 24 hours (based on IBW) | Target peak 20–30 mg/L, trough < 1 mg/L; higher nephrotoxicity than amikacin |
| Tobramycin | 5–7 mg/kg IV every 24 hours (based on IBW) | Target peak 20–30 mg/L, trough < 1 mg/L; preferred aminoglycoside for Pseudomonas in some institutions |
| Ciprofloxacin | 400 mg IV every 8 hours | Avoid if fluoroquinolone used within 90 days; rising resistance limits utility |
| Levofloxacin | 750 mg IV every 24 hours | As above |
| Colistin (polymyxin E) | LD: 300 mg CBA (9 MU) IV x 1; MD: 150 mg CBA (4.5 MU) IV q12h | Reserve for XDR gram-negatives; nephrotoxicity monitoring essential; see pathogen-specific section |
| Polymyxin B | LD: 2.5 mg/kg IV x 1; MD: 1.25–1.5 mg/kg IV q12h | Less nephrotoxic than colistin; no renal dose adjustment needed (not renally eliminated) |
MRSA Coverage — Add When Indicated
Add an anti-MRSA agent when any of the following apply:1
- Unit MRSA prevalence > 10–20% among S. aureus ICU isolates
- Patient has known MRSA colonization (nasal or respiratory)
- Prior MRSA infection
- Prior IV antibiotics within 90 days (MRSA risk factor)
- Gram stain of respiratory sample showing gram-positive cocci in clusters
| Agent | Standard Adult Dose | Key Notes |
|---|---|---|
| Vancomycin | LD: 25–30 mg/kg IV x 1; MD: 15–20 mg/kg IV q8–12h (target AUC/MIC 400–600 using Bayesian software, or trough 15–20 mg/L if AUC monitoring unavailable) | First-line anti-MRSA; monitor renal function; 2020 consensus recommends AUC-guided dosing over trough-based monitoring |
| Linezolid | 600 mg IV/PO every 12 hours | No renal adjustment; monitor platelets (thrombocytopenia with courses > 14 days); avoid with serotonergic agents; good lung penetration |
Renal Dose Adjustments — Combination Therapy Agents
| Agent | CrCl 30–50 mL/min | CrCl 10–29 mL/min | CrCl < 10 mL/min or HD | CRRT |
|---|---|---|---|---|
| Ceftazidime | 1 g IV q12h | 1 g IV q24h | 1 g IV q48h (after HD) | 1–2 g IV q12h |
| Aztreonam | 1 g IV q8h | 500 mg – 1 g IV q12h | 500 mg IV q12h (after HD) | 2 g IV q12h |
| Amikacin | Extend interval; monitor levels | Extend interval to q24–48h; levels essential | Post-HD dosing; redose based on levels | 10 mg/kg q24h; monitor levels |
| Gentamicin / Tobramycin | Extend interval; monitor levels | Extend interval to q24–48h; levels essential | Post-HD dosing; redose based on levels | 2–3 mg/kg q24–48h; monitor levels |
| Ciprofloxacin | 400 mg IV q12h | 200 mg IV q12h | 200 mg IV q12h | 400 mg IV q12h |
| Colistin (CBA) | Reduce MD by 25–50% | Reduce MD by 50% | Consult pharmacist; supplement post-HD | Reduced dose; institution-specific |
| Vancomycin | Adjust per AUC monitoring | Adjust per AUC monitoring; may require q24h dosing | Post-HD redosing based on levels | 15–20 mg/kg q24–48h; monitor levels |
| Linezolid | No adjustment | No adjustment | No adjustment (removed by HD; give after HD) | No adjustment |
11.4 Extended Infusion Beta-Lactam Strategy
For critically ill patients with VAP (especially those with septic shock or infections caused by organisms with elevated MICs), extended or continuous infusion of beta-lactam antibiotics optimizes pharmacokinetic-pharmacodynamic (PK-PD) target attainment:7
| Infusion Strategy | Mechanism | Evidence |
|---|---|---|
| Standard infusion (30 min) | Intermittent bolus dosing | Adequate for organisms with low MICs; standard approach |
| Extended infusion (3–4 hours) | Maintains drug concentration above MIC for ~60–70% of the dosing interval | Improved clinical cure and survival in meta-analyses of critically ill patients; recommended as first-line approach in severe infections |
| Continuous infusion (24-hour) | Maintains constant drug concentration above MIC | Maximum PK-PD optimization; requires dedicated IV line; stability considerations |
Recommended extended infusion dosing:
| Agent | Extended Infusion Dose | Infusion Duration | Stability at Room Temperature |
|---|---|---|---|
| Piperacillin-tazobactam | 4.5 g IV q6h | Over 3–4 hours | 24 hours |
| Cefepime | 2 g IV q8h | Over 3–4 hours | 24 hours |
| Meropenem | 1–2 g IV q8h | Over 3 hours | 4–8 hours (stability is a key limitation) |
| Ceftazidime | 2 g IV q8h | Over 3–4 hours | 24 hours |
12. Antibiotic De-escalation
12.1 Principles
De-escalation — narrowing the spectrum of empiric antibiotics based on culture results — is a cornerstone of antibiotic stewardship in VAP management.18
Timeline for de-escalation:
| Timepoint | Action |
|---|---|
| 0–6 hours | Initiate empiric broad-spectrum antibiotics after obtaining cultures |
| 24–48 hours | Review preliminary Gram stain and culture results; reassess clinical trajectory |
| 48–72 hours | Final culture identification and susceptibility results available → actively de-escalate |
| Day 3–5 | Reassess clinical response; stop antibiotics if VAP is excluded (cultures negative + clinical improvement + alternative diagnosis identified) |
12.2 De-escalation Approach
| Scenario | Action |
|---|---|
| Cultures identify a specific pathogen with susceptibilities | Narrow to the most targeted effective agent; discontinue combination therapy |
| MRSA not isolated and nasal MRSA screen negative | Discontinue vancomycin/linezolid (negative nasal MRSA swab has > 95% NPV for MRSA VAP) |
| Cultures negative at 48–72 hours | If patient is clinically improving and VAP diagnosis is in doubt, consider stopping antibiotics; if clinical concern remains, continue narrowed therapy |
| Pseudomonas identified and susceptible | De-escalate to a single agent with activity; continue monotherapy (combination therapy for the full course is not recommended when the organism is susceptible) |
| ESBL-producing organism | Typically requires carbapenem (meropenem or imipenem); de-escalate from broader combination to carbapenem monotherapy |
12.3 MRSA Nasal Screening for De-escalation
The MRSA nasal swab (PCR or culture) has emerged as a valuable tool for guiding empiric MRSA therapy in VAP:9
| Test Result | MRSA VAP NPV | Action |
|---|---|---|
| Negative nasal MRSA screen | 95–99% | Strongly consider discontinuing empiric vancomycin/linezolid |
| Positive nasal MRSA screen | Low PPV (~15–30%) | Does not confirm MRSA VAP; MRSA colonization is common; continue empiric MRSA coverage until respiratory cultures finalize |
13. Duration of Antibiotic Therapy
13.1 Short-Course Therapy — 7 Days
The 2016 guidelines strongly recommend 7 days of antibiotic therapy for VAP, rather than longer courses (10–21 days), for most patients.1210
Evidence:
- A landmark multicenter RCT (n = 401) compared 8 days vs 15 days of antibiotic therapy for VAP. The 8-day group had equivalent 28-day mortality (18.8% vs 17.2%) and clinical cure rates, with significantly fewer antibiotic-free days (mean 13.1 vs 8.7 days, p < 0.001). No difference in recurrence except for non-fermenting gram-negative bacilli (primarily Pseudomonas), where 8-day therapy was associated with a higher recurrence rate (40.6% vs 25.4%), though without impact on mortality.10
- A subsequent meta-analysis confirmed that short-course therapy (7–8 days) is associated with more antibiotic-free days, reduced emergence of resistant organisms, and similar clinical outcomes compared with longer courses.11
13.2 Exceptions — When Longer Courses May Be Warranted
| Situation | Suggested Duration | Rationale |
|---|---|---|
| Non-fermenting gram-negatives (Pseudomonas, Acinetobacter, Stenotrophomonas) | 7–14 days (individualized) | Higher recurrence with 7-day courses; consider extending if slow clinical response |
| MRSA pneumonia | 7–14 days | Some experts recommend 10–14 days based on limited data; clinical response should guide duration |
| Lung abscess or necrotizing pneumonia | 14–21 days or longer | Inadequate source control with shorter courses |
| Empyema | 14–21 days minimum | Requires adequate drainage plus prolonged antibiotics |
| Immunocompromised patients | Individualized (typically 14+ days) | Impaired host defenses may necessitate longer treatment |
| Bacteremia from VAP | Minimum 7 days from first negative blood culture | Standard approach for bacteremia |
13.3 Procalcitonin-Guided Antibiotic Discontinuation
Procalcitonin (PCT) can be used as an adjunctive tool to guide antibiotic discontinuation in VAP:15
| PCT Criterion | Recommendation |
|---|---|
| PCT < 0.5 ng/mL or decline ≥ 80% from peak | Consider antibiotic discontinuation if clinically improved |
| PCT persistently elevated or rising | Continue or reassess antibiotics; consider treatment failure, inadequate source control, or secondary infection |
| Serial PCT measurements | Obtain baseline at VAP diagnosis, then every 48–72 hours |
Important: PCT-guided algorithms should complement — not replace — clinical judgment. PCT should not be used as a sole criterion for continuing antibiotics in an improving patient.
14. Inhaled Antibiotics as Adjunctive Therapy
14.1 Indications
Inhaled (aerosolized) antibiotics are considered as adjunctive therapy (in addition to IV antibiotics, not as a substitute) for VAP caused by MDR gram-negative organisms that are susceptible only to polymyxins or aminoglycosides, or when clinical response to IV therapy alone is inadequate.112
14.2 Available Inhaled Agents
| Agent | Dose (Nebulized) | Frequency | Vehicle | Key Notes |
|---|---|---|---|---|
| Tobramycin | 300 mg | Every 12 hours | Preservative-free solution | Most commonly used inhaled aminoglycoside for VAP |
| Amikacin | 400 mg | Every 12 hours | Preservative-free solution | Alternative to tobramycin |
| Colistimethate (colistin) | 75–150 mg CBA (2–4 MU) | Every 8–12 hours | Reconstitute in sterile water; use within 24 hours of reconstitution | First-line inhaled agent for XDR gram-negatives (Acinetobacter, Pseudomonas) |
14.3 Administration Requirements
| Requirement | Details |
|---|---|
| Nebulizer type | Vibrating mesh nebulizer preferred (e.g., Aerogen Solo); jet nebulizers are less efficient; ultrasonic nebulizers should be avoided with some formulations |
| Ventilator settings | Increase inspiratory time (if possible); consider reducing flow rate to optimize aerosol delivery; target I:E ratio of 1:1 |
| Circuit placement | Place nebulizer in the inspiratory limb, 15–30 cm proximal to the Y-piece |
| HME removal | Remove any heat-moisture exchanger during nebulization; replace with heated humidifier or remove during treatment |
| Monitoring | Monitor for bronchospasm during administration; pre-treat with bronchodilator (albuterol 2.5 mg) 15 minutes before inhaled antibiotic |
| Duration | Continue for the full course of VAP treatment (typically 7 days; may extend for MDR organisms) |
15. Treatment Failure Evaluation
15.1 Definition
Treatment failure should be suspected if there is no clinical improvement or clinical deterioration by 72 hours after initiation of appropriate empiric therapy.12
15.2 Differential Diagnosis of Treatment Failure
| Category | Considerations |
|---|---|
| Incorrect initial diagnosis | Atelectasis, ARDS, pulmonary embolism, pulmonary hemorrhage, drug-induced lung injury, organizing pneumonia, cardiogenic pulmonary edema |
| Resistant or untreated organism | MDR pathogen not covered by empiric regimen; fungal infection; viral pneumonia; Mycobacterium tuberculosis; Nocardia; Pneumocystis jirovecii |
| Inadequate antibiotic dosing | Subtherapeutic drug levels (particularly in augmented renal clearance, obesity, or high-volume fluid resuscitation); consider extended infusion, higher doses, or therapeutic drug monitoring |
| Complication of VAP | Empyema, lung abscess, necrotizing pneumonia requiring drainage or prolonged therapy |
| Superinfection | New organism acquired during treatment (often more resistant than the initial pathogen) |
| Non-pulmonary infection | CLABSI, CAUTI, Clostridioides difficile, intra-abdominal infection, sinusitis |
| Drug fever | Antibiotics themselves can cause persistent fever |
15.3 Evaluation Steps
- Repeat lower respiratory tract cultures (consider BAL if ETA was initially used)
- Obtain CT chest (more sensitive than portable CXR for empyema, abscess, alternative diagnoses)
- Review antibiotic susceptibilities and assess adequacy of dosing
- Consider therapeutic drug monitoring (vancomycin AUC, aminoglycoside levels, beta-lactam levels if available)
- Evaluate for non-pulmonary sources of infection
- Consider broadening empiric coverage to include XDR gram-negatives and/or fungal pathogens
- Infectious disease consultation recommended for treatment failure
Kalil AC, Metersky ML, Klompas M, et al. “Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society.” Clin Infect Dis. 2016;63(5):e61-e111. ATS/IDSA. DOI: 10.1093/cid/ciw353 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Torres A, Niederman MS, Chastre J, et al. “International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia.” Eur Respir J. 2017;50(3):1700582. ERS/ESICM/ESCMID/ALAT. DOI: 10.1183/13993003.00582-2017 ↩︎ ↩︎ ↩︎ ↩︎ ↩︎ ↩︎
Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM. “Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic ‘blind’ bronchoalveolar lavage fluid.” Am Rev Respir Dis. 1991;143(5 Pt 1):1121-1129. DOI: 10.1164/ajrccm/143.5_Pt_1.1121 ↩︎
Canadian Critical Care Trials Group. “A randomized trial of diagnostic techniques for ventilator-associated pneumonia.” N Engl J Med. 2006;355(25):2619-2630. DOI: 10.1056/NEJMoa052904 ↩︎
Schuetz P, Wirz Y, Sager R, et al. “Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections.” Cochrane Database Syst Rev. 2017;10:CD007498. DOI: 10.1002/14651858.CD007498.pub3 ↩︎ ↩︎
Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. “Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia.” N Engl J Med. 2004;350(5):451-458. DOI: 10.1056/NEJMoa032655 ↩︎
Roberts JA, Abdul-Aziz MH, Davis JS, et al. “Continuous versus intermittent beta-lactam infusion in severe sepsis: a meta-analysis of individual patient data from randomized trials.” Am J Respir Crit Care Med. 2016;194(6):681-691. DOI: 10.1164/rccm.201601-0024OC ↩︎
Leone M, Bechis C, Baumstarck K, et al. “De-escalation versus continuation of empirical antimicrobial treatment in severe sepsis: a multicenter non-blinded randomized noninferiority trial.” Intensive Care Med. 2014;40(10):1399-1408. DOI: 10.1007/s00134-014-3411-8 ↩︎
Parente DM, Cunha CB, Engemann JJ, Hollenbeck BK, Timbrook TT. “The clinical utility of methicillin-resistant Staphylococcus aureus (MRSA) nasal screening to rule out MRSA pneumonia: a diagnostic meta-analysis with antimicrobial stewardship implications.” Clin Infect Dis. 2018;67(1):1-7. DOI: 10.1093/cid/ciy024 ↩︎
Chastre J, Wolff M, Fagon JY, et al. “Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial.” JAMA. 2003;290(19):2588-2598. PneumA Trial. DOI: 10.1001/jama.290.19.2588 ↩︎ ↩︎
Pugh R, Grant C, Cooke RP, Dempsey G. “Short-course versus prolonged-course antibiotic therapy for hospital-acquired pneumonia in critically ill adults.” Cochrane Database Syst Rev. 2015;8:CD007577. DOI: 10.1002/14651858.CD007577.pub3 ↩︎
Solé-Lleonart C, Rouby JJ, Blot S, et al. “Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis.” Anesthesiology. 2017;126(5):890-908. DOI: 10.1097/ALN.0000000000001570 ↩︎